Loading institutional data...
Loading institutional data...
Held by 2,891 of 5,944 reporting institutions (100th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $375.21 today, the market must believe free cash flow compounds 7.0%/yr for a decade (off $20.8B normalized FCF).
The market's 7.0% is in line with its 9-yr track record.
2-stage DCF · 0.91B shares · net debt $54.0B
mean 9.8% · volatility σ 21% · implied rate exceeded in 6/9 yrs
Central path = implied 7.0%/yr growth; shaded band = ±1σ (21%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $447.57B 100.0% | $400.28B 100.0% | $371.62B 100.0% | $324.16B 100.0% | $287.60B 100.0% | $257.14B 100.0% | $242.16B 100.0% | $226.25B 100.0% | $201.16B 100.0% | $184.84B 100.0% |
| Cost of Revenue | $50.66B 11.3% | $46.69B 11.7% | $38.77B 10.4% | $33.70B 10.4% | $31.03B 10.8% | $30.75B 12.0% | $28.12B 11.6% | $27.00B 11.9% | $24.11B 12.0% | $24.42B 13.2% |
| Cost of Products | — | — | — | — | — | — | — | — | $24.11B 12.0% | $24.42B 13.2% |
| Selling, General & Admin | $59.59B 13.3% | $53.01B 13.2% | $54.63B 14.7% | $47.78B 14.7% | $42.58B 14.8% | $41.70B 16.2% | $35.19B 14.5% | $34.07B 15.1% | $29.56B 14.7% | $28.40B 15.4% |
| Total Operating Expenses | $428.60B 95.8% | $367.99B 91.9% | $339.26B 91.3% | $295.73B 91.2% | $263.63B 91.7% | $234.74B 91.3% | $222.47B 91.9% | $208.90B 92.3% | $185.95B 92.4% | $171.91B 93.0% |
| Operating Income | $18.96B 4.2% | $32.29B 8.1% | $32.36B 8.7% | $28.43B 8.8% | $23.97B 8.3% | $22.41B 8.7% | $19.68B 8.1% | $17.34B 7.7% | $15.21B 7.6% | $12.93B 7.0% |
| Interest Expense | $4.00B 0.9% | $3.91B 1.0% | $3.25B 0.9% | $2.09B 0.6% | $1.66B 0.6% | $1.66B 0.6% | $1.70B 0.7% | $1.40B 0.6% | $1.19B 0.6% | $1.07B 0.6% |
| Pretax Income | $14.70B 3.3% | $20.07B 5.0% | $29.11B 7.8% | $26.34B 8.1% | $22.31B 7.8% | $20.74B 8.1% | $17.98B 7.4% | $15.94B 7.0% | $14.02B 7.0% | $11.86B 6.4% |
| Income Tax Expense | $1.89B 0.4% | $4.83B 1.2% | $5.97B 1.6% | $5.70B 1.8% | $4.58B 1.6% | $4.97B 1.9% | $3.74B 1.5% | $3.56B 1.6% | $3.20B 1.6% | $4.79B 2.6% |
| Net Income | $12.06B 2.7% | $14.40B 3.6% | $22.38B 6.0% | $20.12B 6.2% | $17.29B 6.0% | $15.40B 6.0% | $13.84B 5.7% | $11.99B 5.3% | $10.56B 5.2% | $7.02B 3.8% |
| Per Share | ||||||||||
| EPS (Basic) | $13.28 | $15.64 | $24.12 | $21.47 | $18.33 | $16.23 | $14.55 | $12.45 | $10.95 | $7.37 |
| EPS (Diluted) | $13.23 | $15.51 | $23.86 | $21.18 | $18.08 | $16.03 | $14.33 | $12.19 | $10.72 | $7.25 |
| Weighted Avg Shares (Basic) | 908.0M | 921.0M | 928.0M | 937.0M | 943.0M | 949.0M | 951.0M | 963.0M | 964.0M | 952.0M |
| Weighted Avg Shares (Diluted) | 911.0M | 929.0M | 938.0M | 950.0M | 956.0M | 961.0M | 966.0M | 983.0M | 985.0M | 968.0M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 49% of free cash flow, leaving room to grow it and fund buybacks. Last year: $7.9B dividends + $5.5B buybacks = $13.5B returned on $16.1B FCF.
9 consecutive years of dividend increases · 16%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A balanced mix of reinvestment and shareholder returns.
Modest payoff on reinvested capital. Current ROIC on all capital: 7%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $24.4B covers the $6.1B due within a year 4.0× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Coverage is adequate but not comfortable. Effective rate ~5.1% on $78.4B of debt.
Cash of $24.4B fully covers short-term debt of $6.1B.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
Where each multiple sits in its own 14-yr range · 68th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 11.9 | 11.6 | 12.0 | 10.8 | 10.4 | 10.4 | 11.7 | 11.3 |
| SG&A | 15.1 | 14.5 | 16.2 | 14.8 | 14.7 | 14.7 | 13.2 | 13.3 |
| Operating Income | 7.7 | 8.1 | 8.7 | 8.3 | 8.8 | 8.7 | 8.1 | 4.2 |
| Income Tax | 1.6 | 1.5 | 1.9 | 1.6 | 1.8 | 1.6 | 1.2 | 0.4 |
| Net Income | 5.3 | 5.7 | 6.0 | 6.0 | 6.2 | 6.0 | 3.6 | 2.7 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on UNH: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
Peers = companies sharing UNH's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position